Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 3/20 | 0.44 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334410 | 0.91 | HPGD (0.45) | HPGDSTAT3NR2F2POLBGFER | |
| SCHEMBL6334408 | 0.91 | HPGD (0.45) | HPGDSTAT3NR2F2POLBGFER | |
| SCHEMBL6335058 | 0.81 | DHPS (0.37) | STAT3NR2F2POLBL3MBTL1MAPK1 | |
| SCHEMBL6332762 | 0.81 | MEN1 (0.44) | HPGDSTAT3NR2F2POLBL3MBTL1 | |
| SCHEMBL6332759 | 0.81 | MEN1 (0.44) | HPGDSTAT3NR2F2POLBL3MBTL1 | |
| SCHEMBL27579335 | 0.80 | MAPK1 (0.40) | STAT3NR2F2POLBL3MBTL1MAPK1 | |
| SCHEMBL6336984 | 0.78 | HTT (0.52) | STAT3NR2F2MAPK1KMT2AMAPT | |
| SCHEMBL6336980 | 0.78 | HTT (0.52) | STAT3NR2F2MAPK1KMT2AMAPT | |
| SCHEMBL6336890 | 0.77 | HPGD (0.48) | HPGDPOLBGFERKDRL3MBTL1 | |
| SCHEMBL27572530 | 0.77 | MAPK1 (0.38) | STAT3NR2F2POLBL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | claimed |
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | HPGD 416/4885STAT3 2251/4885NR2F2 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.